Cannabigerol (CBG) Cannabinoid Research

Cannabigerol (CBG) Research Dashboard


Primary Studies


Related Studies


Total Studies

Clinical Studies


Double-blind human trials


Clinical human trials

Pre-Clinical Studies




Animal studies


Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 36 studies associated with Cannabigerol (CBG).

Here is a small sampling of Cannabigerol (CBG) studies by title:

Components of the Cannabigerol (CBG) Research Dashboard

  • Top medical conditions associated with Cannabigerol (CBG)
  • Proven effects in clinical trials for Cannabigerol (CBG)
  • Receptors associated with Cannabigerol (CBG)
  • Individual study details for Cannabigerol (CBG)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Cannabigerol (CBG)

Description of Cannabigerol (CBG)

The plant-based (phytocannabinoid) CBG was discovered in 1964 (CBG-C5). In its acid form CBG is the parent molecule from which all other plant-based cannabinoids are metabolized. CBD has antioxidant and anti-inflammatory properties,

Other Names:


Cannabigerol (CBG) Properties and Effects

Muscle relaxant, Analgesia, Sedative, May be anti-proliferative in cases of prostate and colorectal cancer, Antibacterial (MRSA), Appetite stimulant (in cases of anorexia, cachexia), Anti-parasitical (leishmania), pre-clinical trials suggest potential benefits in treating neurological disorders such as Huntington's Disease.

Cannabigerol (CBG) Receptor Binding

Low affinity for CB1 (CBG binds to CB1 with a Ki of 760nM) and CB2, significant agonist for TRPV1 and TRPA1, inhibitor (antagonist) of TRPM8. CBG is a moderate inhibitor of 5HT1A serotonin receptors and an agonist at alpha-2-andrenergic-receptor sites. CBD activates PPARγ.

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.